JP Morgan analyst Doug Anmuth maintains Amazon.com (NASDAQ:AMZN) with a Overweight and raises the price target from $175 to $185.
Cellectis Announces Preliminary Clinical Data For UCART22 In ALL And UCART123 In AML
UCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion
UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient
